Раздел 1.7
 
  1. Turcotte R. Giant cell tumor of bone. Orthopedic Clinics 2006; 37.1: 35-51.
  2. Baena-Ocampo L., Del C., Ramirez-Perez E et al. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol 2009; 13(1):16-21. DOI: 10.1016/j.anndiagpath.2008.07.005
  3. Larsson S.E., Lorentzon R., Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopatho-logical study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Joint Surg Am 1975; 57(2):167-73.
  4. Rendina D., Mossetti G., Soscia E. et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; (421):218-24. DOI: 10.1097/00000118702.46373.3.
  5. Rendina D., Mossetti G., Soscia E. et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; (421):218-24. DOI: 10.1097/00000118702.46373.3.
  6. Sinnott B.P., Patel M. Giant cell lesion of the jaw as a presenting feature of Noonan syndrome. BMJ Case Rep 2018; 2018. DOI: 10.1136/bcr-2017-224115.
  7. van den Berg H., Schreuder W.H., Jongmans M. et al. Multiple giant cell lesions in a patient with Noonan syndrome with multiple lentigines. Eur J Med Genet 2016; 59(8):425-8. DOI: 10.1016/j.ejmg.2016.05.013.
  8. Bartsch O. Case report: Noonan syndrome with multiple giant cell lesions and review of the literature. Am J Med Genet A 2012;158A9):2283-9. DOI: 10.1002/ajmg.a.35493
  9. Chan J.Y. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci. 2011; 7(8):1122-44.
  10. Schwartz H.S., Juliao S.F., Sciadini M.F. et al. Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer. 1995 Mar 01; 75(5):1094-9.
  11. Flanagan A.M., Larousserie F. et al. Giant Cell Tumour of Bone. In: WHO Classification of Tumours of Soft Tissue and Bone, 5" ed., IARC, Geneva 2020. P. 440.
  12. Amelio J.M., Rockberg J., Hernandez R.K. et al. Population-based study of giant cell tumor of bone in Sweden (1983-2011). Cancer Epidemiol 2016; 42:82-9. DOI: 10.1016/j.canep.2016.03.014.
  13. Bertoni F., Bacchini P., Staals E.L. Malignancy in giant cell tumor of bone. Cancer 2003; 97(10):2520-9. DOI: 10.1002/cncr. 11359.
  14. Rock M.G., Sim F.H., Unni K.K. et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am 1986; 68(7):1073-9.
  15. Sato K., Yamamura S., Iwata H. et al. Giant cell-rich osteosarcoma: a case report. Nagoya J Med Sci 1996; 59(3-4):151-7.
  16. López-Pousa A., Broto J.M., Garrido T., Vázquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015; 17(6):419-430.
  17. Hemingway F., Taylor R., Knowles H.J., Athanasou N.A. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone. 2011; 48:938-944.
  18. Clézardin P. The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bull Cancer. 2011; 98(7):837-846.
  19. Hiraga T. Bone metastasis: interaction between cancer cells and bone microenvironment. J Oral Biosci. 2019; 61(2):95-98.
  20. Balla P., Moskovszky L., Sapi Z. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology. 2011; 59(3):376-389.
  21. Lindeman J.H.N., Hanemaaijer R., Mulder A. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol. 2004;165(2):593-600.
  22. Park J.K., Rosen A., Saffitz J.E. Expression of cathepsin K and tartrate-resistant acid phosphatase is not confined to osteoclasts but is a general feature of multinucleated giant cells: systematic analysis. Rheumatol (United Kingdom) 2013; 52(8):1529-1533.
  23. Gorunova L., Vult von Steyern F., Storlazzi C.T. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Gene Chromosome Canc. 2009; 48(7):583-602.
  24. Schwartz H.S., Allen G.A., Butler M.G. Telomeric associations. Appl Cytogenet J Assoc Cytogenet Technol. 1990; 16(6):133.
  25. Yamamoto H., Ishihara S., Toda Y., Oda Y. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Med Mol Morphol. 2019
  26. Yamamoto H., Iwasaki T., Yamada Y. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 2018; 73:41-50.
  27. Behjati S., Tarpey P.S., Presneau N. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45(12):1479-1482.
  28. Cleven A., Hocker S., Briaire-de Bruijn I. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015; 39(11):1576-1583.
  29. Moskovszky L., Szuhai K., Krenács T. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Gene Chromosome Canc. 2009; 48(6):468-479.
  30. Lieveld M., Bodson E., De Bock G. Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis. Virchows Arch. 2014; 465(6):703-713.
  31. Oda Y., Sakamoto A., Saito T. Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology. 2001; 39(6):629-637.
  32. Balke M., Ahrens H., Streitbuerger A. et al. Treatment options for recurrent giant cell tumours of bone. J Cancer Res Clin Oncol 2009; 135(1):149-58.
  33. Gaston C.L., Bhumbra R., Watanuki M., Abudu A.T., Carter S.R., Jeys L.M., Tillman R.M., Grimer R.J. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br. 2011 Dec; 93(12):1665-9. doi: 10.1302/0301-620X.93B12.27663. PMID: 22161931.
  34. Gouin F., Rochwerger A.R., Di Marco A., Rosset P., Bonnevialle P., Fiorenza F., Anract P. Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer. 2014 Sep; 50(14):2425-31. doi: 10.1016/j.ejca.2014.06.003. Epub 2014 Jul 23. PMID: 25088085.
  35. Jones K.B., DeYoung B.R., Morcuende J.A., Buckwalter J.A. Ethanol as a local adjuvant for giant cell tumor of bone. Iowa Orthop J. 2006; 26:69-76. PMID: 16789453; PMCID: PMC1888590.
  36. Balke M., Schremper L., Gebert C., Ahrens H., Streitbuerger A., Koehler G., Hardes J., Gosheger G. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008 Sep; 134(9):969-78. doi: 10.1007/s00432-008-0370-x. Epub 2008 Mar 6. PMID: 18322700.
  37. Martin C., McCarthy E.F. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J. 2010; 30:69-75. PMID: 21045974; PMCID: PMC2958273.
  38. Prosser G.H., Baloch K.G., Tillman R.M., Carter S.R., Grimer R.J. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res. 2005 Jun; (435):211-8. doi: 10.1097/01.blo.0000160024.06739.ff. PMID: 15930941.
  39. Zhou M., Yang H., Chen K., et al. Surgical treatment of giant cell tumors of the sacrum and spine combined with pre-operative transarterial embolization. Oncol Lett. 2013; 6(1):185–90.
  40. Ruka W., Rutkowski P., Morysiński T., et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 2010;78(2):494–8.
  41. Cornelis F., Truchetet M.E., Amoretti N., et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. Bone. 2014; 58:11–6.
  42. Mattei T.A., Ramos E., Rehman A.A., Shaw A., Patel S.R., Mendel E. Sustained long-term complete regression of a giant cell tumor of the spine after treatment with Denosumab. Spine J. 2014; 14(7):e15–21.
  43. Yamamoto M., Fukushima T., Sakamoto S., et al. Giant cell tumor of the sphenoid bone: long-term follow-up of two cases after chemotherapy. Surg Neurol. 1998; 49(5):547–52.
  44. Tse L.F., Wong K.C., Kumta S.M., Huang L., Chow T.C., Griffith J.F. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2008; 42(1):68-73.
  45. Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone. 2011; 49(1):71-76.
  46. Lau C.P.Y., Huang L., Wong K.C., Kumta S.M. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res. 2013; 54(6):439-449.
  47. Balke M., Campanacci L., Gebert C. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Canc. 2010; 10(1):462.
  48. Yu X., Xu M., Xu S., Su Q. Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett. 2013; 5(2):447-451.
  49. Lipplaa A., Kroep J.R., van der Heijden L. Adjuvant zoledronic acid in high‐risk giant cell tumor of bone: a multicenter randomized phase II trial. Oncol. 2019; 24(7)889
  50. Тарарыкова А.А., Феденко А.А., Мусаев Э.Р. Современный взгляд на лечение гигантоклеточной опухоли кости в эру деносумаба. Обзор литературы // Саркомы костей, мягких тканей и опухоли кожи. 2020; 12(4):11–21.
  51. Thomas D.M. RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 2012; 24(4):397-403. DOI: 10.1097/cco.0b013e328354c129.
  52. Cummings S.R., San Martin J., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-65. DOI: 10.1056/NEJMoa0809493.
  53. Rifkin W.D. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:2390-91.
  54. Thomas D., Henshaw R., Skubitz K. et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11(3):275-80. DOI: 10.1016/S1470-2045(10)70010-3.
  55. Palmerini E., Chawla N.S., Ferrari S. et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur J Cancer 2017; 76:118-24. DOI: 10.1016/j.ejca.2017.01.028
  56. Ueda T., Morioka H., Nishida Y. et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol 2015; 26(10):2149-54.DOI: 10.1093/annonc/mdv307.
  57. Chawla S., Blay J.Y., Rutkowski P. et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20(12):1719-29. DOI: 10.1016/S1470-2045(19)30663-1.
  58. Тарарыкова А.А. Диссертация на соискание ученой степени кандидата медицинских наук по специальности онкология, лучевая терапия, 2022 г. «Оптимизация методов лечения больных гигантоклеточной опухолью кости»
  59. Chawla S., Blay J.Y., Rutkowski P., Le Cesne A., Reichardt P. Gelderblom H., Grimer R.J., Choy E., Skubitz K., Seeger L., Schuetze S.M., Henshaw R., Dai T., Jandial D., Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec; 20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6. PMID: 31704134.
  60. van Dam P.A., Verhoeven Y., Trinh X.B., Wouters A., Lardon F., Prenen H., Smits E., Baldewijns M., Lammens M. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2019 Jan; 133:85-91. doi: 10.1016/j.critrevonc.2018.10.011. Epub 2018 Nov 3. PMID: 30661662.
  61. Liede A., Hernandez R.K., Wade S.W., Bo R., Nussbaum N.C., Ahern E., Dougall W.C., Smyth M.J. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology. 2018 Sep 5; 7(12):e1480301. doi: 10.1080/2162402X.2018.1480301. PMID: 30524886; PMCID: PMC6279336.
  62. Ahern E., Harjunpää H., Barkauskas D., Allen S., Takeda K., Yagita H., Wyld D., Dougall W.C., Teng M.W.L., Smyth M.J. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin Cancer Res. 2017 Oct 1; 23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20. PMID: 28634284.
  63. Toda Y., Kohashi K., Yamamoto H., Ishihara S., Ito Y., Susuki Y., Kawaguchi K., Kiyozawa D., Takamatsu D., Kinoshita I., Yamada Y., Maehara J., Kimura A., Tamiya S., Taguchi K., Matsunobu T., Matsumoto Y., Nakashima Y., Mawatari M., Oda Y. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment. Sci Rep. 2021 Jul 20; 11(1):14821. doi: 10.1038/s41598-021-94022-w. PMID: 34285260; PMCID: PMC8292371.
  64. Thongchot S., Duangkaew S., Yotchai W., Maungsomboon S., Phimolsarnti R., Asavamongkolkul A., Thuwajit P., Thuwajit C., Chandhanayingyong C. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis. Hum Cell. 2023 Jan; 36(1):456-467. doi: 10.1007/s13577-022-00823-0. Epub 2022 Dec 2. PMID: 36456782; PMCID: PMC9813176.
  65. Benner B., Good L., Quiroga D., Schultz T.E., Kassem M., Carson W.E., Cherian M.A., Sardesai S., Wesolowski R. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Drug Des Devel Ther. 2020 May 4; 14:1693-1704. doi: 10.2147/DDDT.S253232. PMID: 32440095; PMCID: PMC7210448.
  66. Cassier P.A., Italiano A., Gomez-Roca C.A., Le Tourneau C., Toulmonde M., Cannarile M.A., Ries C., Brillouet A., Müller C., Jegg A.M., Bröske A.M., Dembowski M., Bray-French K., Freilinger C., Meneses-Lorente G., Baehner M., Harding R., Ratnayake J., Abiraj K., Gass N., Noh K., Christen R.D., Ukarma L., Bompas E., Delord J.P., Blay J.Y., Rüttinger D. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug; 16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12. PMID: 26179200.
  67. Lamb Y.N. Pexidartinib: First Approval. Drugs. 2019 Nov; 79(16):1805-1812. doi: 10.1007/s40265-019-01210-0. Erratum in: Drugs. 2020 Mar;80(4):447. doi: 10.1007/s40265-020-01280-5. PMID: 31602563; PMCID: PMC7044138.
  68. Tap W. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020 Sep;16(25):1875-1878. doi: 10.2217/fon-2020-0307. Epub 2020 Aug 5. PMID: 32755241.
  69. Mun SH, Park PSU, Park-Min KH. The M-CSF receptor in osteoclasts and beyond. Exp Mol Med. 2020 Aug; 52(8):1239-1254. doi: 10.1038/s12276-020-0484-z. Epub 2020 Aug 17. PMID: 32801364; PMCID: PMC8080670.
  70. Smeester B.A., Slipek N.J., Pomeroy E.J., Laoharawee K., Osum S.H., Larsson A.T., Williams K.B., Stratton N., Yamamoto K., Peterson J.J., Rathe S.K., Mills L.J., Hudson W.A., Crosby M.R., Wang M., Rahrmann E.P., Moriarity B.S., Largaespada D.A. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone. 2020 Jul; 136:115353. doi: 10.1016/j.bone.2020.115353. Epub 2020 Apr 3. PMID: 32251854.
  71. Tap W.D., Wainberg Z.A., Anthony S.P., Ibrahim P.N., Zhang C., Healey J.H., Chmielowski B., Staddon A.P., Cohn A.L., Shapiro G.I., Keedy V.L., Singh A.S., Puzanov I., Kwak E.L., Wagner A.J., Von Hoff D.D., Weiss G.J., Ramanathan R.K., Zhang J., Habets G., Zhang Y., Burton E.A., Visor G., Sanftner L., Severson P., Nguyen H., Kim M.J., Marimuthu A., Tsang G., Shellooe R., Gee C., West B.L., Hirth P., Nolop K., van de Rijn M., Hsu H.H., Peterfy C., Lin P.S., Tong-Starksen S., Bollag G. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015 Jul 30; 373(5):428-37. doi: 10.1056/NEJMoa1411366. PMID: 26222558.
  72. Dharmani C., Wang E., Salas M., McCabe C., Diggs A., Choi Y., Jiang J., Keedy V.L. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience. Future Oncol. 2022 Apr; 18(13):1595-1607. doi: 10.2217/fon-2021-1475. Epub 2022 Feb 2. PMID: 35105158.
  73. Verspoor F.G.M., Mastboom M.J.L., Hannink G., Maki R.G., Wagner A., Bompas E., Desai J., Italiano A., Seddon B.M., van der Graaf W.T.A., Blay J.Y., Brahmi M., Eberst L., Stacchiotti S., Mir O., van de Sande M.A.J., Gelderblom H., Cassier P.A. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y. PMID: 31601938; PMCID: PMC6786996.
  74. Cassier P.A., Italiano A., Gomez-Roca C., Le Tourneau C., Toulmonde M., D'Angelo S.P., Weber K., Loirat D., Jacob W., Jegg A.M., Michielin F., Christen R., Watson C., Cannarile M., Klaman I., Abiraj K., Ries C.H., Weisser M., Rüttinger D., Blay J.Y., Delord J.P. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer. 2020 Dec; 141:162-170. doi: 10.1016/j.ejca.2020.09.038. Epub 2020 Nov 5. PMID: 33161240.
  75. Fan M., Zhang G., Xie M., Liu X., Zhang Q., Wang L. Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone. Curr Oncol. 2022 Oct 13; 29(10):7655-7671. doi: 10.3390/curroncol29100605. PMID: 36290882; PMCID: PMC9600077.
  76. Ishida-Kitagawa N., Tanaka K., Bao X., Kimura T., Miura T., Kitaoka Y., Hayashi K., Sato M., Maruoka M., Ogawa T., Miyoshi J., Takeya T. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12). J Biol Chem. 2012 May 18; 287(21):17493-17502. doi: 10.1074/jbc.M111.324194. Epub 2012 Mar 26. PMID: 22451653; PMCID: PMC3366812.
  77. Hiruma Y., Hirai T., Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem Biophys Res Commun. 2011 Jun 10; 409(3):424-9. doi: 10.1016/j.bbrc.2011.05.015. Epub 2011 May 8. PMID: 21586272.
  78. Wang J., Sun J., Liu L.N., Flies D.B., Nie X., Toki M., Zhang J., Song C., Zarr M., Zhou X., Han X., Archer K.A., O'Neill T., Herbst R.S., Boto A.N., Sanmamed M.F., Langermann S., Rimm D.L., Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019 Apr; 25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4. PMID: 30833750; PMCID: PMC7175920.